These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16338419)

  • 21. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
    Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
    Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential impact of hypoxia on the success of oncolytic virotherapy.
    Hay JG
    Curr Opin Mol Ther; 2005 Aug; 7(4):353-8. PubMed ID: 16121701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of transcriptionally regulated oncolytic adenoviruses.
    Ko D; Hawkins L; Yu DC
    Oncogene; 2005 Nov; 24(52):7763-74. PubMed ID: 16299536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential of tumour cells for delivering oncolytic viruses.
    Raykov Z; Rommelaere J
    Gene Ther; 2008 May; 15(10):704-10. PubMed ID: 18356816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses.
    Li H; Zeng Z; Fu X; Zhang X
    Cancer Res; 2007 Aug; 67(16):7850-5. PubMed ID: 17699791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
    Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
    Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.
    Nguyen TL; Tumilasci VF; Singhroy D; Arguello M; Hiscott J
    Cell Microbiol; 2009 Jun; 11(6):889-97. PubMed ID: 19388908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control.
    Mohr I
    Oncogene; 2005 Nov; 24(52):7697-709. PubMed ID: 16299530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function.
    Fang L; Huang Y; Hu X; Sun L; He X; Hu H; Pu Y; Cao X; Luo H; Pan S; Gu J; Su C
    Chem Biol Interact; 2009 Sep; 181(1):1-7. PubMed ID: 19523934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting gene-virotherapy of cancer and its prosperity.
    Liu XY
    Cell Res; 2006 Nov; 16(11):879-86. PubMed ID: 17102812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ReVOLT: radiation-enhanced viral oncolytic therapy.
    Advani SJ; Mezhir JJ; Roizman B; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):637-46. PubMed ID: 17011442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Oncolytic virotherapy for human solid tumors].
    Fujiwara T
    Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
    Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor.
    Carette JE; Graat HC; Schagen FH; Mastenbroek DC; Rots MG; Haisma HJ; Groothuis GM; Schaap GR; Bras J; Kaspers GJ; Wuisman PI; Gerritsen WR; van Beusechem VW
    Virology; 2007 Apr; 361(1):56-67. PubMed ID: 17184803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein.
    Bian H; Wilden H; Fournier P; Peeters B; Schirrmacher V
    Int J Oncol; 2006 Dec; 29(6):1359-69. PubMed ID: 17088973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
    Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncolytic adenoviruses as antiglioma agents.
    Jiang H; McCormick F; Lang FF; Gomez-Manzano C; Fueyo J
    Expert Rev Anticancer Ther; 2006 May; 6(5):697-708. PubMed ID: 16759161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic vaccinia virus: from bedside to benchtop and back.
    Thorne SH
    Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.